Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Recursion Pharmaceuticals ( (RXRX) ) just unveiled an announcement.
On July 8, 2025, Recursion Pharmaceuticals acquired full ownership of the ENPP1 inhibitor program, REV102, from Rallybio, aiming to develop a potential first-in-class oral treatment for hypophosphatasia (HPP), a rare genetic disorder. This acquisition is expected to accelerate the development of REV102, leveraging Recursion’s AI/experimental platform to enhance insights and delivery of the treatment, which could significantly impact patients with limited access to existing therapies and potentially reduce long-term management costs.
The most recent analyst rating on (RXRX) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
Recursion Pharmaceuticals’ overall score reflects its strong revenue growth and strategic partnerships, counterbalanced by profitability challenges and reliance on external financing. Technical indicators are moderately positive, but valuation metrics remain unattractive due to ongoing losses. Corporate restructuring efforts aim to bolster financial stability, but risks from program discontinuations persist.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical stage TechBio company focused on industrializing drug discovery by decoding biology. The company utilizes its proprietary Recursion OS platform, which integrates diverse technologies and machine-learning algorithms to explore biological and chemical datasets. Recursion operates on a large experimental and computational scale, aiming to advance the future of medicine. Headquartered in Salt Lake City, the company is a founding member of BioHive, the Utah life sciences industry collective, and has offices in Montréal, New York, London, and the Oxford area.
Average Trading Volume: 25,758,490
Technical Sentiment Signal: Sell
Current Market Cap: $2B
See more insights into RXRX stock on TipRanks’ Stock Analysis page.